AC Immune SA (ACIU)
3.29
+0.05
(+1.54%)
USD |
NASDAQ |
Nov 21, 16:00
3.285
0.00 (0.00%)
After-Hours: 20:00
AC Immune Enterprise Value: 137.84M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 137.84M |
| November 20, 2024 | 132.89M |
| November 19, 2024 | 135.86M |
| November 18, 2024 | 122.50M |
| November 15, 2024 | 127.94M |
| November 14, 2024 | 163.56M |
| November 13, 2024 | 122.01M |
| November 12, 2024 | 115.08M |
| November 11, 2024 | 125.97M |
| November 08, 2024 | 128.93M |
| November 07, 2024 | 135.86M |
| November 06, 2024 | 118.05M |
| November 05, 2024 | 132.89M |
| November 04, 2024 | 103.21M |
| November 01, 2024 | 109.14M |
| October 31, 2024 | 93.31M |
| October 30, 2024 | 106.18M |
| October 29, 2024 | 110.13M |
| October 28, 2024 | 109.14M |
| October 25, 2024 | 114.09M |
| October 24, 2024 | 109.14M |
| October 23, 2024 | 113.10M |
| October 22, 2024 | 120.03M |
| October 21, 2024 | 116.07M |
| October 18, 2024 | 122.01M |
| Date | Value |
|---|---|
| October 17, 2024 | 129.92M |
| October 16, 2024 | 127.94M |
| October 15, 2024 | 128.93M |
| October 14, 2024 | 127.94M |
| October 11, 2024 | 140.81M |
| October 10, 2024 | 142.79M |
| October 09, 2024 | 147.73M |
| October 08, 2024 | 139.82M |
| October 07, 2024 | 148.72M |
| October 04, 2024 | 146.74M |
| October 03, 2024 | 147.73M |
| October 02, 2024 | 156.64M |
| October 01, 2024 | 183.35M |
| September 30, 2024 | 186.32M |
| September 27, 2024 | 176.21M |
| September 26, 2024 | 171.27M |
| September 25, 2024 | 170.28M |
| September 24, 2024 | 173.24M |
| September 23, 2024 | 167.31M |
| September 20, 2024 | 170.28M |
| September 19, 2024 | 170.28M |
| September 18, 2024 | 164.34M |
| September 17, 2024 | 147.52M |
| September 16, 2024 | 128.72M |
| September 13, 2024 | 119.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.6107M
Minimum
Dec 22 2022
413.52M
Maximum
Jan 15 2020
178.43M
Average
160.48M
Median
Jan 19 2022
Enterprise Value Benchmarks
| CRISPR Therapeutics AG | 2.015B |
| Addex Therapeutics Ltd | 4.450M |
| NLS Pharmaceutics Ltd | 14.00M |
| Molecular Partners AG | 28.94M |
| MoonLake Immunotherapeutics | 2.784B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.364M |
| Revenue (Quarterly) | 29.47M |
| Total Expenses (Quarterly) | 21.07M |
| EPS Diluted (Quarterly) | 0.0578 |
| Profit Margin (Quarterly) | 21.59% |
| Earnings Yield | -13.95% |
| Normalized Earnings Yield | -12.74 |